Diabetes Drug May Reduce Heart Failure Risks
Recent research has revealed that a diabetes medication might lower heart failure risks for some patients. A study, published in Nature Medicine, looked at dapagliflozin, a drug typically used for managing type 2 diabetes, and its potential to prevent heart failure among individuals with specific genetic traits tied to heart muscle diseases known as cardiomyopathy.
This study included data from the DECLARE-TIMI 58 trial, which involved over 12,000 adults with type 2 diabetes and heightened cardiovascular risks. Among these, 121 participants had inherited genetic variants that could increase their likelihood of developing cardiomyopathy.
After tracking their health for about 4.2 years, researchers found that dapagliflozin significantly reduced the chances of hospitalization due to heart failure in those with these genetic variants compared to those without.
While the drug improved outcomes for all patients, its effectiveness was particularly notable among those with the genetic variants, as hospitalization rates were about eight times lower. Alarmingly, among carriers without prior heart failure, 12.8% in the placebo group developed heart failure, while none who received dapagliflozin experienced such events.
Dr. Shinwan Kany, a co-author of the study and a visiting scientist at Mass General Brigham, highlighted the importance of these findings for preventive healthcare. He explained that previously, knowing about a genetic risk often meant that patients received little guidance on prevention strategies. This study shows that tools like dapagliflozin are available to help reduce risks for these individuals.
Experts caution that while the results are promising, they need further validation due to the small number of participants with genetic variants. Dr. Andrew Freeman, a cardiologist not involved in the study, called the findings “important and thought-provoking.” He noted that exploring genetic screening for heart failure could lead to more targeted preventive care.
As the study indicates the potential benefits of SGLT2 inhibitors like dapagliflozin, physicians may soon use genetic screenings to identify high-risk patients earlier. This could allow for timely treatment, even before any symptoms appear, such as shortness of breath or fluid retention.
In conclusion, the study points towards a future where genetics can guide more personalized and effective heart failure prevention strategies, but any medication decisions should always be made in consultation with a healthcare provider.
